Circuit Upholds Dismissal of Fraud Claims Against Genzyme

A securities fraud action against a pharmaceutical company that sells natural biological drugs failed because the plaintiffs did not "convey a cogent and compelling inference of deceitful intent, or reckless disregard of the truth, on the part of defendants," the U.S. Circuit Court of Appeals for the First Circuit has ruled.

Sign up for a free trial now!'s Elite 15-day trial gives you:

  • All access pass to legal news across ALM's Network
  • News by Practice Area, available exclusively on
  • The free InPractice digital newsletter
  • Personalized legal news on the mobile App

During and after your trial, you'll receive the benefits of an ALM digital membership, including a subscription to the Newswire digital newsletter.